|
ZSCAN22 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.06860000035492E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.64631999999276E-05 |
| Normal-vs-Stage2 |
1.990010E-02 |
| Normal-vs-Stage3 |
1.31449999996036E-06 |
| Normal-vs-Stage4 |
1.425950E-04 |
| Stage1-vs-Stage2 |
2.546400E-01 |
| Stage1-vs-Stage3 |
9.069800E-02 |
| Stage1-vs-Stage4 |
4.378200E-01 |
| Stage2-vs-Stage3 |
3.710200E-02 |
| Stage2-vs-Stage4 |
1.295240E-01 |
| Stage3-vs-Stage4 |
6.381600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.24279999996957E-06 |
| Normal-vs-AfricanAmerican |
1.661860E-02 |
| Normal-vs-Asian |
3.579100E-03 |
| Caucasian-vs-AfricanAmerican |
7.275000E-01 |
| Caucasian-vs-Asian |
5.239400E-01 |
| AfricanAmerican-vs-Asian |
9.056200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.26409999999944E-05 |
| Normal-vs-Female |
8.26850000024137E-07 |
| Male-vs-Female |
8.443000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.36219999999654E-05 |
| Normal-vs-Age(41-60Yrs) |
4.33300000002301E-06 |
| Normal-vs-Age(61-80Yrs) |
2.34330000004057E-06 |
| Normal-vs-Age(81-100Yrs) |
5.719600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.324200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.441600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.466800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.880800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.911000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.256800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.657600E-03 |
| Classical-VS-Follicular |
1.962900E-03 |
| Classical-VS-Other |
9.408400E-02 |
| Classical-VS-Normal |
2.596400E-04 |
| Tall-VS-Follicular |
4.770000E-01 |
| Tall-VS-Other |
7.744600E-01 |
| Tall-VS-Normal |
7.20479999993806E-07 |
| Follicular-VS-Other |
5.272200E-01 |
| Follicular-VS-Normal |
3.93889999950048E-07 |
| Other-VS-Normal |
8.761100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.54432999999177E-05 |
| Normal-vs-N1 |
1.55984999999914E-05 |
| N0-vs-N1 |
2.605000E-01 |
|
|
